Person:
SALMAN, ANDAÇ

Profile Picture

Email Address

Birth Date

Research Projects

Organizational Units

OrgUnit Logo
Organizational Unit

Job Title

Last Name

SALMAN

First Name

ANDAÇ

Name

Filters

2020 - 20212
Reset filters

Settings

Start date: 2020 × Subject: chronic urticaria ×

Search Results

Now showing 1 - 2 of 2
  • Thumbnail Image
    PublicationOpen Access
    Real-life data on the effectiveness and safety of omalizumab in monotherapy or combined for chronic spontaneous urticaria: a retrospective cohort study
    (TAYLOR & FRANCIS LTD, 2020-02-17) SALMAN, ANDAÇ; Salman, Andac; Ergun, Tulin; Maria Gimenez-Arnau, Ana
    Background: The real-life data on the effectiveness and safety of omalizumab in chronic spontaneous urticaria (CSU) with validated methods are scarce. There is also a lack of information on the use of combination treatments. Methods: A retrospective cohort study was done to evaluate the effectiveness and safety of omalizumab in real-life conditions. The patients with CSU treated with omalizumab between 2015 and 2018 were included. The response to therapy was evaluated using urticaria activity score over 7 days (UAS7) and urticaria control test (UCT). Results: A total of 106 patients were included. A complete response (CR) (UAS7:0) and a well-controlled activity (WCA) (UAS7:1 to <6) were observed in 50 (47.2%) and 35 (33%) patients, respectively. The number of patients with an UCT score >= 12 was also significantly increased. Higher rates of CR/WCA were observed with omalizumab monotherapy compared to combination with antihistamines. The combination of dapsone, colchicine, and omalizumab provided additional benefit in a small group. Conclusion: Treatment with omalizumab provided a rapid and sustainable improvement in real-life settings. The use of omalizumab as monotherapy or combined with antihistamines does not show differences in the treatment response. The combination of omalizumab with immunomodulatory agents might be of benefit in selected cases.
  • Thumbnail Image
    PublicationOpen Access
    The global impact of the COVID-19 pandemic on the management and course of chronic urticaria
    (WILEY, 2021-03) SALMAN, ANDAÇ; Kocaturk, Emek; Salman, Andac; Cherrez-Ojeda, Ivan; Criado, Paulo Ricardo; Peter, Jonny; Comert-Ozer, Elif; Abuzakouk, Mohamed; Agondi, Rosana Camara; Al-Ahmad, Mona; Altrichter, Sabine; Arnaout, Rand; Arruda, Luisa Karla; Asero, Riccardo; Bauer, Andrea; Ben-Shoshan, Moshe; Bernstein, Jonathan A.; Bizjak, Mojca; Boccon-Gibod, Isabelle; Bonnekoh, Hanna; Bouillet, Laurence; Brzoza, Zenon; Busse, Paula; Campos, Regis A.; Carne, Emily; Conlon, Niall; Criado, Roberta F.; de Souza Lima, Eduardo M.; Demir, Semra; Dissemond, Joachim; Gunaydin, Sibel Dogan; Dorofeeva, Irina; Ensina, Luis Felipe; Ertas, Ragip; Ferrucci, Silvia Mariel; Figueras-Nart, Ignasi; Fomina, Daria; Franken, Sylvie M.; Fukunaga, Atsushi; Gimenez-Arnau, Ana M.; Godse, Kiran; Goncalo, Margarida; Gotua, Maia; Grattan, Clive; Guillet, Carole; Inomata, Naoko; Jakob, Thilo; Karakaya, Gul; Kasperska-Zajac, Alicja; Katelaris, Constance H.; Kosnik, Mitja; Krasowska, Dorota; Kulthanan, Kanokvalai; Kumaran, M. Sendhil; Lang, Claudia; Ignacio Larco-Sousa, Jose; Lazaridou, Elisavet; Leslie, Tabi Anika; Lippert, Undine; Llosa, Oscar Calderon; Makris, Michael; Marsland, Alexander; Medina, Iris, V; Meshkova, Raisa; Palitot, Esther Bastos; Parisi, Claudio A. S.; Pickert, Julia; Ramon, German D.; Rodriguez-Gonzalez, Monica; Rosario, Nelson; Rudenko, Michael; Rutkowski, Krzysztof; Sanchez, Jorge; Schliemann, Sibylle; Sekerel, Bulent Enis; Serpa, Faradiba S.; Serra-Baldrich, Esther; Song, Zhiqiang; Soria, Angele; Staevska, Maria; Staubach, Petra; Tagka, Anna; Takahagi, Shunsuke; Thomsen, Simon Francis; Treudler, Regina; Vadasz, Zahava; Rodrigues Valle, Solange Oliveira; Van Doorn, Martijn B. A.; Vestergaard, Christian; Wagner, Nicola; Wang, Dahu; Wang, Liangchun; Wedi, Bettina; Xepapadaki, Paraskevi; Yucel, Esra; Zalewska-Janowska, Anna; Zhao, Zuotao; Zuberbier, Torsten; Maurer, Marcus
    Introduction The COVID-19 pandemic dramatically disrupts health care around the globe. The impact of the pandemic on chronic urticaria (CU) and its management are largely unknown. Aim To understand how CU patients are affected by the COVID-19 pandemic; how specialists alter CU patient management; and the course of CU in patients with COVID-19. Materials and Methods Our cross-sectional, international, questionnaire-based, multicenter UCARE COVID-CU study assessed the impact of the pandemic on patient consultations, remote treatment, changes in medications, and clinical consequences. Results The COVID-19 pandemic severely impairs CU patient care, with less than 50% of the weekly numbers of patients treated as compared to before the pandemic. Reduced patient referrals and clinic hours were the major reasons. Almost half of responding UCARE physicians were involved in COVID-19 patient care, which negatively impacted on the care of urticaria patients. The rate of face-to-face consultations decreased by 62%, from 90% to less than half, whereas the rate of remote consultations increased by more than 600%, from one in 10 to more than two thirds. Cyclosporine and systemic corticosteroids, but not antihistamines or omalizumab, are used less during the pandemic. CU does not affect the course of COVID-19, but COVID-19 results in CU exacerbation in one of three patients, with higher rates in patients with severe COVID-19. Conclusions The COVID-19 pandemic brings major changes and challenges for CU patients and their physicians. The long-term consequences of these changes, especially the increased use of remote consultations, require careful evaluation.